Last week, the Senate Finance Committee questioned CEOs from various pharmaceutical companies as part of an ongoing investigation into drug pricing. Seven executives from major drug manufacturers gave Congressional testimony and answered questions regarding the high price of prescription drugs. Many believe hospital industry prices will be placed under the magnifying glass next. What lessons from the pharma hearing can be applied to hospitals?

Also in Policy Brief:

• Grassley Renews Investigation on Tax-Exempt Hospitals
• Good Choices Ahead: Incentivizing Positive Patient Decisions
• A Look at the Federal Register
• In Other News